Tags

Type your tag names separated by a space and hit enter

Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Diabet Med. 2011 May; 28(5):560-6.DM

Abstract

AIMS

Postprandial hyperglycaemia in patients with Type 2 diabetes mellitus has been linked to the development of cardiovascular disease. This study compared the effects of mealtime (thrice-daily) nateglinide with once-daily glyburide on postprandial glucose levels in patients with Type 2 diabetes and postprandial hyperglycaemia.

METHODS

Patients with Type 2 diabetes aged ≥ 21 years with 2-h postprandial glucose levels ≥ 11.1 mmol/l, HbA(1c) of 6.5-8.5% (48-69 mmol/mol) and BMI of 22-30 kg/m(2) were randomized to 6 weeks' double-blind treatment with nateglinide 120 mg three times daily prior to meals, or glyburide 5 mg once daily before breakfast. The primary endpoint was the baseline-adjusted change in plasma glucose from preprandial (fasting plasma glucose) to 2-h postprandial glucose levels (2-h postprandial glucose excursion) at 6 weeks.

RESULTS

Patients were randomized to nateglinide (n = 122) or glyburide (n = 110). The treatment groups were similar in terms of age, gender, BMI, fasting plasma glucose, 2-h postprandial glucose and HbA(1c). At endpoint, nateglinide recipients had significantly greater reductions than those receiving glyburide in both the 2-h (-2.4 vs. -1.6 mmol/l; P = 0.02) and 1-h (-1.7 vs. -0.9 mmol/l; P = 0.016) postprandial glucose excursions. Adverse events, most commonly symptomatic hypoglycaemia, were reported in 26% of recipients of glyburide and 22% of recipients of nateglinide. Episodes of suspected mild hypoglycaemia were reported in 24% of recipients of glyburide and 10% of recipients of nateglinide.

CONCLUSIONS

Nateglinide leads to greater reductions in postprandial glucose excursions and is associated with a lower risk of hypoglycaemia than glyburide in this selected population of patients with Type 2 diabetes.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Bellomo Damato A
Department of Emergency and Organ Transplantation, Section on Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Università degli Studi di Bari Aldo Moro, Bari, Italy.
Stefanelli G
No affiliation info available
Laviola L
No affiliation info available
Giorgino R
No affiliation info available
Giorgino F
No affiliation info available

MeSH

AdultAgedAged, 80 and overCardiovascular DiseasesCyclohexanesDiabetes Mellitus, Type 2Diabetic AngiopathiesDouble-Blind MethodFastingFemaleGlyburideGlycated Hemoglobin AHumansHyperglycemiaMiddle AgedNateglinidePhenylalaninePostprandial Period

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21204958

Clinical Trial Links

Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion in Patients With Type 2 Diabetes

Citation

Bellomo Damato, A, et al. "Nateglinide Provides Tighter Glycaemic Control Than Glyburide in Patients With Type 2 Diabetes With Prevalent Postprandial Hyperglycaemia." Diabetic Medicine : a Journal of the British Diabetic Association, vol. 28, no. 5, 2011, pp. 560-6.
Bellomo Damato A, Stefanelli G, Laviola L, et al. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. Diabet Med. 2011;28(5):560-6.
Bellomo Damato, A., Stefanelli, G., Laviola, L., Giorgino, R., & Giorgino, F. (2011). Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. Diabetic Medicine : a Journal of the British Diabetic Association, 28(5), 560-6. https://doi.org/10.1111/j.1464-5491.2010.03219.x
Bellomo Damato A, et al. Nateglinide Provides Tighter Glycaemic Control Than Glyburide in Patients With Type 2 Diabetes With Prevalent Postprandial Hyperglycaemia. Diabet Med. 2011;28(5):560-6. PubMed PMID: 21204958.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia. AU - Bellomo Damato,A, AU - Stefanelli,G, AU - Laviola,L, AU - Giorgino,R, AU - Giorgino,F, PY - 2011/1/6/entrez PY - 2011/1/6/pubmed PY - 2011/7/27/medline SP - 560 EP - 6 JF - Diabetic medicine : a journal of the British Diabetic Association JO - Diabet Med VL - 28 IS - 5 N2 - AIMS: Postprandial hyperglycaemia in patients with Type 2 diabetes mellitus has been linked to the development of cardiovascular disease. This study compared the effects of mealtime (thrice-daily) nateglinide with once-daily glyburide on postprandial glucose levels in patients with Type 2 diabetes and postprandial hyperglycaemia. METHODS: Patients with Type 2 diabetes aged ≥ 21 years with 2-h postprandial glucose levels ≥ 11.1 mmol/l, HbA(1c) of 6.5-8.5% (48-69 mmol/mol) and BMI of 22-30 kg/m(2) were randomized to 6 weeks' double-blind treatment with nateglinide 120 mg three times daily prior to meals, or glyburide 5 mg once daily before breakfast. The primary endpoint was the baseline-adjusted change in plasma glucose from preprandial (fasting plasma glucose) to 2-h postprandial glucose levels (2-h postprandial glucose excursion) at 6 weeks. RESULTS: Patients were randomized to nateglinide (n = 122) or glyburide (n = 110). The treatment groups were similar in terms of age, gender, BMI, fasting plasma glucose, 2-h postprandial glucose and HbA(1c). At endpoint, nateglinide recipients had significantly greater reductions than those receiving glyburide in both the 2-h (-2.4 vs. -1.6 mmol/l; P = 0.02) and 1-h (-1.7 vs. -0.9 mmol/l; P = 0.016) postprandial glucose excursions. Adverse events, most commonly symptomatic hypoglycaemia, were reported in 26% of recipients of glyburide and 22% of recipients of nateglinide. Episodes of suspected mild hypoglycaemia were reported in 24% of recipients of glyburide and 10% of recipients of nateglinide. CONCLUSIONS: Nateglinide leads to greater reductions in postprandial glucose excursions and is associated with a lower risk of hypoglycaemia than glyburide in this selected population of patients with Type 2 diabetes. SN - 1464-5491 UR - https://www.unboundmedicine.com/medline/citation/21204958/Nateglinide_provides_tighter_glycaemic_control_than_glyburide_in_patients_with_Type_2_diabetes_with_prevalent_postprandial_hyperglycaemia_ DB - PRIME DP - Unbound Medicine ER -